Eisai is a Japanese research-based pharmaceutical company with a focus on neurology and oncology. The company has gained international recognition for its work in Alzheimer's disease, including collaboration with Biogen on treatments targeting the underlying causes of the condition. Eisai markets oncology medicines globally and has established commercial operations across the United States, Europe, and Asia.

For international investors, Eisai is a Japan-based global pharmaceutical company with established franchises in neurology and oncology. The company achieved significant international attention with the US approval of its Alzheimer's disease treatment, developed in partnership with Biogen, representing a potential breakthrough in a disease area of enormous global unmet medical need. This pipeline achievement, combined with Eisai's established oncology products marketed globally with Merck, makes it a closely watched name among healthcare investors.